Bayesian Gets A Boost With Guidance, But Technique Still Not For Everyone
This article was originally published in The Gray Sheet
Executive Summary
The complex calculations of Bayesian statistics are not likely to become standard for FDA device submissions anytime soon, but they could help streamline clinical trials in many more instances, CDRH's top statistics official says